Scientists probe kidney tissue to uncover how diabetes drugs shield kidneys

NCT ID NCT07444203

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study examines kidney tissue from adults with diabetic kidney disease who are already having a kidney biopsy or surgery as part of their regular care. Researchers want to see if people taking SGLT2 inhibitors (a type of diabetes medicine) show different biological patterns in their kidney tissue compared to those not taking them. The goal is to understand how these medicines may protect the kidneys and link those patterns to changes in kidney function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SGLT2 inhibitors (a type of diabetes medicine)
What this could lead to
If successful, this study could reveal how SGLT2 inhibitors protect the kidneys, pointing toward better treatments for diabetic kidney disease.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to everyone with kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Penn Presbyterian Medical Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.